530 results about "Liver adenocarcinoma" patented technology

The invention discloses a meso-porous silicon nano-drug carrier with both reduction responsiveness and targeting ability and a preparation method thereof. Firstly, meso-porous silicon nano-particles are prepared with a sol-gel method, and are developed into a nanometer reservoir of drug molecules; then a disulfide bond is introduced into the surface of the meso-porous silicon nanometer reservoir with a simple chemical modification method and is used as a cohesive tie; secondarily, a biocompatible natural extracellular matrix-collagen molecule is creatively fixed to the surface of the meso-porous silicon nanometer reservoir and is developed into a nanometer encapsulator of the meso-porous silicon nanometer reservoir; and finally a lactobionic acid molecule is modified to the surface of a meso-porous silicon/collagen nanometer compounding system and is used as a specificity receptor of a liver cancer cell membrane surface receptor (ASGP-R) so as to construct a meso-porous silicon/collagen-lactobionic acid multifunctional compound type nano-drug carrier system with both cell specificity targeting ability and reducing substance/enzyme responsiveness.

The present invention relates to the use of cytotoxicity based on the effector function of anti-CDH3 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient for damaging CDH3-expressing cells using antibody effector function. Since CDH3 is strongly expressed in pancreatic, lung, colon, prostate, breast, gastric or liver cancer cells, the present invention is useful in pancreatic, lung, colon, prostate, breast, gastric or liver cancer therapies.

The invention relates to a rat liver cancer model with different liver matrix hardness backgrounds and a preparation method of the rat liver cancer model. The method for preparing the rat liver cancer model with different liver matrix backgrounds is characterized by specifically comprising the following steps of: after grouping the rats, injecting pure carbon tetrachloride to an abdominal region in a hypodermic manner; injecting a carbon tetrachloride-olive oil solution to the abdominal region in the hypodermic manner; detecting through a texture analyzer to form the rat model with different liver matrix hardness; taking liver cancer cells which are in-vitro cultured and grown well and injecting the liver cancer cells to the rat to form hypodermic liver cancer cells; in-situ planting the formed liver cancer tumor source to the rat model with different liver matrix hardness to obtain the rat liver cancer model with different liver matrix hardness backgrounds. The rat liver cancer model with different liver matrix hardness backgrounds can be used for well displaying liver cancer malignant pathological characteristics under the liver matrix hardness interference, simulating and reproducing pathological characteristics of clinical liver matrix hardening background liver cancer and solving the problems that an ideal experiment system, an animal model and the like are lacked in reaching the development of the liver cancer due to the liver matrix hardness changes.

The invention provides the application of carbon nanotube-chitosan-phycocyanin complex in the preparation of antitumor drugs. The carbon nanotube-chitosan-phycocyanin complex is composed of multi-walled carbon nanotubes, Chitosan and spirulina phycocyanin are formed by non-covalent combination. The complex has good growth inhibitory effect on breast cancer MCF-7 cells and liver cancer HepG2 cells, especially under the irradiation of near-infrared light and visible light. The inhibitory effect was further strengthened, and all showed the characteristics of killing tumor cells. As an anti-tumor biomedical material, the carbon nanotube-chitosan-phycocyanin composite provided by the invention has broad prospects in photodynamic therapy and photothermal therapy of tumor cells.

The invention relates to dibenzo iodonium salts represented by the following structural formula (I), and discloses a preparation method and an application thereof. In in-vitro experiments, the iodonium salts substantially inhibit the growths of cells of human-sourced pancreatic cancer, stomach cancer, colon cancer and other malignant tumors, and provide substantially killing effects against cells of ovarian cancer, lung cancer, liver cancer, leukemia, glioma, bone marrow cancer and other malignant tumors. In animal experiments, with the salts, the growths of human pancreatic cancer and colon cancer xenografts in nude mice can be substantially inhibited. The compounds can be used in developing novel antitumor medicines. (I) is shown below.

The invention discloses a liver-cancer-targeted doxorubicin-supporting silica-gold composite material, and a preparation method and application thereof. The composite material comprises silica-gold nanometer core-shell particles, a targeting adhesion peptide and doxorubicin; doxorubicin is subjected to chemical modification for forming A SH-PEG-Dox prodrug, and the prodrug is linked to silica-gold nanometer core-shell particles via Au-S bonds; and the targeting adhesion peptide is linked to the silica-gold nanometer core-shell particles via Au-S bonds. The material is good in biological compatibility, has specific optical properties and good targeting property, the material can enable the supported medicine to be transferred to liver cancer cells and rapidly releases the medicine, and the material has the cooperative treatment effects of chemotherapy and thermotherapy.

The invention discloses a compound lithocarolsA-F, a preparation method and application thereof in preparation of antitumor drugs. The compound lithocarolsA-F is isolated from a fermentation culture of marine fungi Phomopsis lithocarpus FS508. Experiments prove that the IC50 values of the compound lithocarolsA-F on liver cancer cells HepG-2, breast cancer cells MCF-7, glioma cells SF-268 and non-small cell lung cancer cells A549 are 10.5-87.7 muM, showing that the compound lithocarolsA-F has relatively significant antitumor activity and can be used for preparing antitumor drugs.

The invention belongs to the biological medicine field, in particular relating to the use of a high efficiency small interfering RNA for preparing a tumor migration inhibition drug. The high efficiency small interfering RNA can silence the expression of survivin, change the adhesive force of breast cancer, gastric cancer and liver cancer cells against IV collagen, and inhibit the migrating ability of the breast cancer, gastric cancer and liver cancer cells at two-and three-dimensional levels. The small interfering RNA can also prepare the drug for inhibiting the tumor migration.

The invention relates to a preparation method of hydronopyl triethyl ammonium iodide, and an application of the prepared hydronopyl triethyl ammonium iodide in preparation of an inhibitor for treating tumor. The compound has obvious inhibition effect for tumor cells, and the preparation method of hydronopyl triethyl ammonium iodide is characterized in that hydronopyl chlorine is reacted to sodium iodide to prepare hydronopyl iodine, and the hydronopyl iodine is reacted to triethylamine to obtain hydronopyl triethyl ammonium iodide. The prepared hydronopyl triethyl ammonium iodide has median inhibitory concentration 50 (IC50 ) value of human lung cancer H460 cells, human breast cancer MCF7 cells, human liver cancer SMMC7721 cells, human stomach cancer MK-45 cells as 8.3mum g/ml, 13.25mum g/ml, 2.28mum g/ml and 1.27mum g/ml, which are most basically less than 10 mum g/ml, and partially achieves the requirements of SFDA antitumor drug pharmacodynamics guidance principle, and expresses good antineoplastic activity.